1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,180 | 1,210 | 09.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| Mi | UBS Cuts ABBISKO-B TP to HKD17.5, Reiterates Buy | 2 | AASTOCKS | ||
| 02.07. | Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance | 6 | Benzinga.com | ||
| 02.07. | AstraZeneca, Abbisko partner on lung cancer combination therapy trial | 2 | Seeking Alpha | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 02.07. | ABBISKO-B Forms Strategic Partnership With AstraZeneca PLC Ordinary Shares to Advance NSCLC Clinical Research | 2 | AASTOCKS | ||
| 02.07. | Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC | 160 | PR Newswire | SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered... ► Artikel lesen | |
| 02.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS AND ASTRAZENECA ENTER A STRATEGIC COLLABORATION TO CONDUCT THE CLINICAL TRIAL OF LUMIPODLIN ... | 1 | HKEx | ||
| 29.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 26.06. | ABBISKO-B: ABSK061 Combined with ABSK043 Demonstrates Favorable Safety and Promising Anti-tumor Activity in FGFR2-positive Advanced GC/GEJC Patients | 2 | AASTOCKS | ||
| 26.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS REPORTS PHASE II DATA OF ABSK061 IN COMBINATION WITH ABSK043 IN FGFR2-POSITIVE ADVANCED ... | 1 | HKEx | ||
| 25.06. | Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration | 4 | Forbes | ||
| 24.06. | Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact | 2 | Benzinga.com | ||
| 24.06. | Abbisko Therapeutics, Lilly Expand R&D Alliance | 5 | Contract Pharma | ||
| 24.06. | Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact | 4 | FierceBiotech | ||
| 24.06. | Lilly inks R&D deal worth up to $1.9B with China's Abbisko | 3 | Seeking Alpha | ||
| 24.06. | ABBISKO-B Expands New Drug Collaboration with Eli Lilly on Disease Targets; Potential Deal Size Up to USD1.9B | 4 | AASTOCKS | ||
| 24.06. | Abbisko Therapeutics Deepens R&D Collaboration with Lilly | 140 | PR Newswire | SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered... ► Artikel lesen | |
| 24.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DEEPENS R&D COLLABORATION WITH LILLY | 1 | HKEx | ||
| 22.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 05.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 133,57 | 0,00 % | AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen | |
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 19,180 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,750 | 0,00 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| VIRAX BIOLABS GROUP | 6,340 | -0,31 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | -0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,15 | +0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ENLIVEN THERAPEUTICS | 52,18 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| BEAM THERAPEUTICS | 35,840 | +0,06 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,420 | -0,07 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ABSCI | 11,465 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VOR BIOPHARMA | 19,750 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 48,380 | +0,06 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| TYRA BIOSCIENCES | 33,010 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,520 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
ABBISKO CAYMAN LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,190 Euro und damit -2,46 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.